With the rising demand for cell and gene therapies, the need for manufacturing innovation has never been higher. A surge of deals and expansions in the last year is fuelling the push to truly make these therapies widely available and affordable.
Cell and gene therapies offer huge potential to treat a wide range of diseases including cancer, neurological, and genetic diseases. They have even shown promise to treat the symptoms of Covid-19.
The amount of academic and early-stage biotech research in this area has skyrocketed over the last few years. According to the Alliance for Regenerative Medicine, there are currently 1,220 ongoing clinical trials in this space, 152 of which are at phase III. Despite the global pandemic, investment in this area is also at a record high around the world, with the equivalent of €15.7B invested in 2020, a figure double that of 2019.
But research alone cannot get these complex treatments to patients. “The sharp discrepancy between the high number of products in early-stage development and the still very small number that have made it onto the market,
The post Cell and Gene Therapy Firms Gear up to Revolutionize Manufacturing appeared first on Labiotech.eu.
Published on Thu, 28 Jan 2021 18:26:48 +0000 and sponsored by power automate convert currency